Shao-Lee Lin Sells 18,258 Shares of Cue Biopharma (NASDAQ:CUE) Stock

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Shao-Lee Lin sold 18,258 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $28.62, for a total transaction of $522,543.96. Following the completion of the transaction, the chief executive officer directly owned 705,995 shares of the company’s stock, valued at $20,205,576.90. This represents a 2.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shao-Lee Lin also recently made the following trade(s):

• On Wednesday, August 12th, Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock. The shares were sold at an average price of $27.10, for a total transaction of $1,084,000.00.

Cue Biopharma Stock Up 10.0%

CUE opened at $34.20 on Friday. The firm has a 50-day simple moving average of $29.50 and a two-hundred day simple moving average of $147.28. Cue Biopharma, Inc. has a 52 week low of $4.97 and a 52 week high of $45.50. The company has a market capitalization of $143.64 million, a PE ratio of -1.27 and a beta of 2.47.

Cue Biopharma (NASDAQ:CUE) last posted its earnings results on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%. The firm had revenue of $7.88 million for the quarter, compared to the consensus estimate of $3.00 million.

Institutional Investors Weigh In On Cue Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. lifted its holdings in Cue Biopharma by 730.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after buying an additional 73,000 shares in the last quarter. Squarepoint Ops LLC purchased a new position in shares of Cue Biopharma during the third quarter worth approximately $62,000. Boothbay Fund Management LLC purchased a new position in shares of Cue Biopharma during the third quarter worth approximately $439,000. GC Wealth Management RIA LLC raised its stake in shares of Cue Biopharma by 35.0% during the fourth quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company’s stock valued at $1,415,000 after acquiring an additional 1,200,000 shares in the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc grew its stake in Cue Biopharma by 1,231.2% in the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after purchasing an additional 407,568 shares in the last quarter. 35.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Weiss Ratings upgraded Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Wall Street Zen lowered Cue Biopharma from a “buy” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cue Biopharma presently has a consensus rating of “Sell”.

Key Stories Impacting Cue Biopharma

Here are the key news stories impacting Cue Biopharma this week:

• Positive Sentiment: Second-quarter 2026 revenue was $7.88 million, well above analysts’ $3.00 million estimate. The company also reported recent business highlights, providing potentially supportive news for its clinical-stage immunotherapy pipeline. Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• Neutral Sentiment: Institutional ownership stands at approximately 35.04%, with several funds increasing their positions in recent quarters. This suggests some investor interest, although the reported holdings are relatively small compared with the company’s market capitalization.
• Neutral Sentiment: CEO Shao-Lee Lin sold a combined 58,258 shares for about $1.61 million across August 12 and 13. The filings state that the sales were intended to cover tax-withholding obligations related to vested equity awards, reducing the significance of the transactions as a discretionary bearish signal. Lin still owned 705,995 shares after the latest sale. Cue Biopharma CEO Sells Stock
• Negative Sentiment: Cue Biopharma reported a quarterly loss of $24.14 per share, far worse than the consensus estimate of a $1.69 loss. The company also posted a negative net margin of 59.65% and negative return on equity of 98.30%, highlighting ongoing profitability and potential financing risks.
• Negative Sentiment: Wall Street Zen downgraded CUE from “Buy” to “Hold.” MarketBeat said the broader analyst consensus remains “Sell,” with one tracked analyst carrying a Sell rating. Wall Street Zen Downgrades Cue Biopharma

About Cue Biopharma

Cue Biopharma is a clinical?stage biotechnology company focused on the development of next?generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen?specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early?stage clinical studies.